Following publication of the Research Article by Masataka Sawaki, Yasuaki Muramatsu, Kanae Togo, Thomas Laurent & Hiroji Iwata, titled ‘Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan’, which appeared in a June 2022 issue of Future Oncology (Future Oncology [Lond.] 18(17), 2101–2111 doi: 10.2217/fon-2021-1448), it has been brought to our attention that the following errors required amendment. These have now been corrected.
1. Original text: ‘Data were extracted from a hospital-based medical claims database managed by Medical Data Vision ([MDV]; Tokyo, Japan) for a period of April 2008 through December 2020 (study period)’.
Amended text: ‘Data were extracted from a hospital-based medical claims database managed by Medical Data Vision ([MDV]; Tokyo, Japan) for a period of April 2008 through February 2021 (study period)’.
2. Original text ‘For those who had a surgery record, the first-line treatment was categorized into a gap period of either a <12months or ≥12months following adjuvant endocrine therapy’
Amended text: ‘For those who had a surgery record, the first-line treatment was categorized into a gap period of either a ≤12months or >12months following adjuvant endocrine therapy’
3. Original text ‘Of the 185,865 patients with HR+/HER2- ABC identified in the database, 1074 patients treated with palbociclib were identified from September 2017 to December 2020 and were included in the analysis’
Amended text: ‘Of the 176,984 patients with HR+/HER2- ABC identified in the database, 1074 patients treated with palbociclib were identified from September 2017 to December 2020 and were included in the analysis’
4. Original text: ‘Our analysis included only 68 patients (6.3%) with a ≥12-month gap period after adjuvant endocrine therapy.’
Amended text: ‘Our analysis included only 68 patients (6.3%) with a >12-month gap period after adjuvant endocrine therapy’
5. In table2 ‘Adjuvant endocrine therapy record with ≥12months gap period’ should instead read ‘Adjuvant endocrine therapy record with >12months gap period’. Additionally, ‘Adjuvant endocrine therapy record with <12months gap period’ should instead read ‘Adjuvant endocrine therapy record with ≤12months gap period’
The authors and editors of Future Oncology would like to sincerely apologise for any confusion or inconvenience this may have caused our readers.